ReNeuron Group plc ReNeuron wins Breakthrough of the Year Award

TIDMRENE

ReNeuron Group plc

14 June 2019

 
  14 June 2019    AIM: RENE 
 
 

RNS Reach

ReNeuron Group plc

("ReNeuron" or the "Company")

ReNeuron wins Breakthrough of the Year Award

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is delighted to announce that it has won the 'Breakthrough of the Year' award at last night's 2019 European Mediscience Awards in London.

This award underlines the strong clinical development and commercial progress ReNeuron has made over the past year. This includes positive data from the ongoing Phase 1/2a clinical trial in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and commercialisation of ReNeuron's CTX and hRPC cell therapy programmes in the People's Republic of China.

Olav Hellebø, Chief Executive Officer of ReNeuron, commented:

"We are delighted to have been awarded the Breakthrough of the Year award at the 2019 European Mediscience Awards. We are greatly encouraged by the progress we have made with our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability over the past year and look forward to continuing to advance our clinical and business development activities in the months ahead."

The European Mediscience Awards is one of the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the sector and highlights the achievements of individuals and companies operating within it.

ENDS

 
 Contacts: 
  ReNeuron                                            [phone] 
 Olav Hellebø, Chief Executive Officer 
 Michael Hunt, Chief Financial Officer 
  Buchanan (UK Media/Investor Relations)              [phone] 
 Mark Court, Sophie Wills, Tilly Abraham 
  Argot Partners (US Media/Investor Relations) 
   Stephanie Marks, Claudia Styslinger                [phone] 
  Stifel Nicolaus Europe Limited (NOMAD and 
   Joint Broker) 
   Jonathan Senior, Stewart Wallace, Ben Maddison     [phone] 
  N+1 Singer (Joint Broker) 
   Aubrey Powell, Mark Taylor                         [phone] 
 
 

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off-the-shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRACKQDKKBKDOAD

(END) Dow Jones Newswires

June 14, 2019 06:09 ET (10:09 GMT)